Source: Eur Respir J, 53 (1) 1800869; 10.1183/13993003.00869-2018
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Joseph Jacob, Nikhil Hirani, Coline H.M. van Moorsel, Srinivasan Rajagopalan, John T. Murchison, Hendrik W. van Es, Brian J. Bartholmai, Frouke T. van Beek, Marjolijn H.L. Struik, Gareth A. Stewart, Maria Kokosi, Ryoko Egashira, Anne Laure Brun, Gary Cross, Joseph Barnett, Anand Devaraj, George Margaritopoulos, Ronald Karwoski, Elisabetta Renzoni, Toby M. Maher, Athol U. Wells. Predicting outcomes in rheumatoid arthritis related interstitial lung disease. Eur Respir J, 53 (1) 1800869; 10.1183/13993003.00869-2018

Member's Comments

No comment yet.

Related content which might interest you: Mortality and clinical features in rheumatoid arthritis and interstitial lung disease Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment Year: 2017 Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease Source: Eur Respir J 2016; 47: 588-596 Year: 2016 Characteristics and predictors of outcome in rheumatoid arthritis related ILD Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 Duration of rheumatoid arthritis and the risk of developing interstitial lung disease Source: ERJ Open Res, 7 (1) 00633-2020; 10.1183/23120541.00633-2020 Year: 2021 Interstitial lung disease in patients with rheumatoid arthritis Source: Annual Congress 2008 - Sarcoidosis and other interstitial lung diseases Year: 2008 Methotrexate and rheumatoid arthritis associated interstitial lung disease Source: Eur Respir J, 57 (2) 2000337; 10.1183/13993003.00337-2020 Year: 2021 Rituximab improves interstitial lung disease in rheumatoid arthritis patients Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment Year: 2017 Risk factors of interstitial lung diseases in patients with rheumatoid arthritis. Source: International Congress 2019 – Immune-mediated interstitial lung diseases: from bench to bedside Year: 2019 Analysis of lung diseases associated with rheumatoid arthritis Source: Eur Respir J 2006; 28: Suppl. 50, 307s Year: 2006 Infliximab therapy in interstitial lung disease associated with rheumatoid arthritis Source: Annual Congress 2004 - Fibrosing lung diseases Year: 2004 Pulmonary disease associated with rheumatoid arthritis Source: Virtual Congress 2021 – Exercise tolerance, supportive care and more in non-pulmonary fibrosis interstitial lung diseases Year: 2021 Features and functional deterioration in interstitial lung disease (ILD) asociated to rheumatoid arthritis (RA) Source: International Congress 2019 – Assessment and management of immune-mediated interstitial lung diseases Year: 2019 Interstitial lung abnormalities a risk factor for rheumatoid arthritis interstitial lung disease progression: what's new Source: Breathe, 16 (4) 200223; 10.1183/20734735.0223-2020 Year: 2020 Pragmatic prognostic approach of rheumatoid arthritis-associated interstitial lung disease Source: Eur Respir J 2010; 35: 1206-1208 Year: 2010 Infliximab treatment in patients with interstitial lung disease and rheumatoid arthritis Source: Eur Respir J 2002; 20: Suppl. 38, 587s Year: 2002 The value of biomarkers in the rheumatoid arthritis related interstitial pneumonia Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 Co-morbidities and cause of death in patients with rheumatoid arthritis associated interstitial lung disease Source: International Congress 2015 – Connective tissue disorders Year: 2015 Are risk predicting models useful for estimating survival in rheumatoid arthritis-associated interstitial lung disease? Source: International Congress 2016 – Connective tissue disorders Year: 2016 The lung in rheumatoid arthritis: drugs versus underlying disease Source: Annual Congress 2009 - Lung disease in rheumatoid arthritis treated with tumour necrosis factor inhibitors: a pulmonary perspective Year: 2009 Nintedanib reduces fibrotic markers in the lung in a model of rheumatoid arthritis associated interstitial lung disease Source: International Congress 2016 – ILD pathogenesis Year: 2016